Comparative Pharmacology
Head-to-head clinical analysis: AFEDITAB CR versus DILT CD.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AFEDITAB CR versus DILT CD.
AFEDITAB CR vs DILT-CD
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nifedipine is a dihydropyridine calcium channel blocker that inhibits the influx of calcium ions through L-type channels in vascular smooth muscle and cardiac muscle, leading to vasodilation and reduced myocardial contractility.
Diltiazem inhibits calcium ion influx during depolarization of cardiac and vascular smooth muscle cells, thereby reducing intracellular calcium levels. It decreases sinoatrial and atrioventricular nodal conduction and dilates coronary and peripheral arteries.
30-60 mg orally once daily, extended-release; maximum 90 mg/day.
180-360 mg PO once daily (extended-release); 300-540 mg PO once daily for hypertension; 120-480 mg PO once daily for angina; IV: 0.25 mg/kg bolus over 2 min, then 5-15 mg/hr continuous infusion.
None Documented
None Documented
Terminal elimination half-life is 6-11 hours; prolonged in hepatic impairment and elderly due to reduced clearance
Terminal elimination half-life 7-10 hours; clinically relevant in hepatic impairment (prolonged to 14-20 hours) and in elderly
Renal (80% as inactive metabolites), fecal (15% as metabolites), unchanged drug (<1%)
Renal 2-4% unchanged; extensive hepatic metabolism; 60-70% fecal, 30-40% renal as metabolites
Category C
Category C
Calcium Channel Blocker
Calcium Channel Blocker